

## Short Communication

# Detection of Cytomegalovirus (CMV) in Peripheral Blood Specimens in Patients before Keratoplasty

Omidian J<sup>1</sup>, Sheikhi-Shooshtari F<sup>1\*</sup>, Fazeli M<sup>2</sup>

1. Department of Ophthalmology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
2. WHO Collaborating Center for Reference and Research on Rabies, Pasteur Institute of Iran, Tehran, Iran.

### Abstract

Cytomegalovirus is the most important pathogen affecting transplant recipients and causing significant morbidity and mortality. The prevalence of CMV infections in transplant recipient varies from country to country. The aim of this study was to determine the prognostic value of PCR assay for CMV detection in patients before Keratoplasty. A total of 23 patient samples enrolled in this study from March 2008 to Feb 2010. Based on the result the over all incidence of CMV infection was 39.1 percent (9 positive sample) in PCR assay. In this study, the plasma PCR assay proved to be sensitive and specific in order to detect CMV infections.

**Keywords:** Cytomegalovirus, CMV, Peripheral Blood Specimens, Keratoplasty

### Introduction

Human CMV is a ubiquitous virus infection with worldwide distribution and Human CMV is transmitted from human to human; there is no animal reservoir (1-4). The effects of CMV infection in transplant recipients vary from clinically manifestations of active CMV diseases to allograft injury or loss (5, 6). Despite preventive antiviral medications, CMV infection is still a major cause of morbidity and mortality after bone marrow (BM) or kidney transplantation (5-8). Especially CMV – seropositive patients are at high risk for developing CMV infection (6, 9, 10). CMV disease occurs in the period 28 to 72 day after transplantation. It can affect several organs,

primarily the lung (interstitial pneumonitis) and the gut (6,9). Despite some improvements (new antiviral agent, combination therapy) the fatality rate for CMV pneumonia is still high (5,6,11) Considering CMV infection as the most significant risk factor for the occurrence of CMV disease, early detection of the virus is warranted in order to prevent the progression of the disease (9, 12-14). However, Unlike PCR other assays such as pp65 antigen detection sometimes shows false-negative results due to a low-level expression of the antigen in white blood cells in a small number of patients with definite disease (15, 16). The PCR-based technique has recently been applied to detect CMV - DNA in blood samples provides 100% sensitivity for the diagnosis of CMV infections.

### Methods

**Patient and samples.** All transplant volunteer at the Gholhak laboratory of Tehran undergone laboratory-based buffy coat surveillance for CMV infection. A total of 23 patients, including Keratoplasty volunteer, were

\* **Corresponding author:** Fariba Sheikhi-Shooshtari, Department of Ophthalmology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: [Dr.shaikhi640@gmail.com](mailto:Dr.shaikhi640@gmail.com)

enrolled in the present study from 2008 to 2010. A total 23 samples from these patients were assayed. At each sampling point two 4ml tubes of EDTA-treated blood were collected and Plasma was stored at -20°C after centrifugation for 10 min at 500×g.

**Extraction of CMV DNA.** DNA was extracted from 200µL of plasma and 1.6×10<sup>6</sup> PBL by using the manual phenol chloroform DNA extraction method according to the available protocol and suspended into the tube with 50 µL of elution buffer (17-19).

**Primer design.** The primers were selected and checked by using the two sets of Primer design software program (Gene runner & BioEdit). The conserve regions were amplified using the following primers so that the primers, Forward (5'-CGGTGGAGATACTGCTGAGGTC-3') and Reverse (5'-CAAGGTGCTGCGTGATATGAAC-3') amplified a 250 bp length product in a pp65 gene.

**CMV PCR.** CMV DNA was amplified by PCR technique and primer pairs targeted the glycoprotein B gene: 5'-CGGTGGAGATACTGCTGAGGTC-3'(P1, sense nucleotides 82494-82515), 5'-CAAGGTGCTGCGTGATATGAAC-3'(P2, antisense nucleotides 82729-82750) (26). PCR assay were done in 25 µl tube reaction as the following: 5 pl target DNA, 0.4 pmol of each primer, 0.2 pl deoxy nucleoside triphosphate (containing 25 mM dATP, dCTP, dGTP, and dTTP) and 1 unit of Taq polymerase (Perkin Elmer Cetus, Norwalk, California, USA). PCR was done as below: preheating at 94°C for 3 min, 30 cycles of 94°C for 30 s, 55°C for 30s, 72°C for 30s and a final 72°C for 3min as a final extension step (26). The PCR products were electrophoresed in 1.5% agarose gel, stained with ethidium bromide, and visualized by an ultra-violet (UV) transilluminator (figure 1). Positive and negative controls were tested in each reaction. As positive control, we used a previously confirmed CMV sample (26), and a sample consisting of distilled water was used as a negative control.

**Statistical analysis.** Mann–Whitney U-test was used for the statistical analysis to assess the association between antigenemia and PCR

results. The results were expressed as medians and P values <0.05 were considered significant. P values were calculated using the chi-square test. Pearson correlation and linear regression were used to compare antigenemia and PCR CMV results. Data were analyzed by mean values and standard deviations for frequency and percentages for qualitative categorical variables. SPSS version 13.0 was used to analyze the data. A P value of .05 and 95% confidence intervals was accepted as statistically significant.

## Result


All 23 samples were subjected to analyse by PCR test. The Results showed that 9 out of 23 samples were PCR-positive test. Among all the samples, 9 cases were PCR-positive and 20 cases have IgG antibody to CMV . Results have been summarized in Table1.

From our population, by sex and age hierarchy male and female in range 36-45 and 46-55 have more negative results for antigenemia test, and from other side mal in range 55-65 and female in range from 36-45 shown more positive results for this assay.

Positive results of PCR by sex and age showed similar aspect to antigenemia results, but mal in range from 26-35 and female by range 36-45 have more pcr negative results. By comparison, we assumed that, there was no relation between sex and age with tests results and the differences between observation not enough large to show accurate relationship.

## Discussion

In transplant recipient, the sign of CMV infection are non specific (7, 8) and identification of CMV infections with reasonable accuracy by diagnostic tools are necessary (4-7, 9, 10, 13-15). Managing the CMV infections is a major consideration in providing care to transplant recipients and must be considered for its significant medical importance (7, 8). The polymerase chain reaction based techniques have recently be applied to the detection of various viral pathogens and these tests are recognized as



**Fig. 1.** Results of PCR for 250 bp of the CMV. M: marker; lane 1: positive control; lane 2,3,4: positive samples; lanes 5: negative control

rapid, simple, sensitive, reliable and cost effectiveness tests for detection of viral DNA or RNA( 17-19). PCR based methods has been shown to be an extremely sensitive method for detecting small amount of latent HSV-1 genome as well as CMV DNA in peripheral blood leukocytes in renal transplant recipient(6, 9, 20). Despite preventive antiviral medications which have been used to decrease the incidence, CMV infection is still a major cause of morbidity and allograft rejections. Therefore, early diagnosis of CMV infection and its differentiation from other infections in allograft rejection remains of great importance (5, 21-23). In the present study a PCR technique was optimized and established for the rapid and early detection of HCMV in Keratoplasty volunteer and PCR assay proved to be more sensitive than antigenemia test in detecting CMV viraemia.

In effect by the plasma PCR assay, 174 of 187 episodes of CMV viraemia could be diagnosed, while the AG test was able to detect only 60 episodes. If the specificities of both assays are considered to be 100%, the sensitivities of the plasma PCR assay and AG were found to be 98.7% and 33.7%, respectively. In the current study 4 samples with discordant results were found to be plasma PCR assay negative and AG positive. Likewise, superior sensitivity of plasma PCR assay in comparison with the sensitivity of AG has been reported in different transplant settings (24, 25). In one study the number of subjects with a positive test result was significantly higher for AG than for the qualitative PCR assay and the AG result tended to turn positive earlier than PCR assay result

**Table 1:** summarized test Results

Test	Result	Number	Percent
PCR	+	9	39.1
CMV IgG antibody	+	20	86.9
Only CMV IgG antibody	+	11	47.82
Both	+	9	39.1

did (24). Reason for such a discrepancy is not clear since the protocol used to perform AG appeared not to be substantially different from that followed in our study, and the same PCR method was used. Our data are also in contrast to those reported by Boeck and coworker, who found the sensitivity of the plasma PCR test, is similar to that of AG (24). That study used an in-house-designed PCR assay (26). In agreement with previous report, the AG result globally tended to turn negative earlier than the plasma result after the initiation of Ganciclovir treatment (24). In summary, the CMV plasma PCR assay is more sensitive than AG for the detection of CMV viraemia in transplant recipients.(27,28) In conclusion the advanced molecular techniques such as real-time PCR could be performed for diagnosis and monitoring of anti viral treatment(29,30).

## References

1. Stephen A, Spector MD, Janet L, Davis MD. Cytomegalovirus. Second Edition. Stephen A. Spector MD, Janet L, Davis, MD, Singh MD. 2002.
2. Puchhammer-Stöckl E, Görzer I. Human cytomegalovirus: an enormous variety of strains and their possible clinical significance in the human host. *Future Virology*. 2011;6(2):259-71.
3. Falahi Sh, Ravanshad M, Kenar-Kouhi A, Karimi AM. Short communication: seroprevalence of CMV in women's with spontaneous abortion in kowsar hospital, ilam during 2007-2008. *Modares journal of medical sciences. (Pathobiology)*. 2010;1(2):39-43.
4. Evaluation of acute CMV infection prevalence in kidney transplant recipients using PCR and indirect immunofluorescent techniques. Falahi Sh,

- Soleymanjahi h, Kalantar E, Kenar Kouhi A, Saki Amel. Iranian Journal of Medical Microbiology. 2009;3(2-3):61-5.
5. Sia IG, Patel R. New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients. *Clinical Microbiology Reviews*. 2000;13(1):83-121.
  6. Azevedo LS, Pierrotti LC, Abdala E, et al. Cytomegalovirus infection in transplant recipients. *Clinics*. 2015;70(7):515-23.
  7. Bruminhent J, Razonable RR. Management of cytomegalovirus infection and disease in liver transplant recipients. *World Journal of Hepatology*. 2014;6(6):370-383.
  8. Weikert BC, Blumberg EA. Viral Infection after Renal Transplantation: Surveillance and Management. *Clinical Journal of the American Society of Nephrology : CJASN*. 2008;3(Suppl 2):S76-S86.
  9. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients. *Hematology/Oncology Clinics of North America*. 2011;25(1):151-169.
  10. Bhat V, Joshi A, Sarode R, Chavan P. Cytomegalovirus infection in the bone marrow transplant patient. *World Journal of Transplantation*. 2015;5(4):287-291.
  11. Travi G, Pergam SA. Cytomegalovirus Pneumonia In Hematopoietic Stem Cell Recipients. *Journal of intensive care medicine*. 2014;29(4):200-12.
  12. Rozenblyum EV, Allen UD, Silverman ED, Levy DM. Cytomegalovirus infection in childhood-onset systemic lupus erythematosus. *International journal of clinical Rheumatology*. 2013;8(1):137-46.
  13. Navneet S. Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. *Hematology/Oncology and Stem Cell Therapy*. 5(1):1-30.
  14. Cordero E, Casasola C, Ecarma R, Danguilan R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors.. *Transplant Proc*. 2012;44(3):694-700.
  15. Pang XL, Chui L, Fenton J, LeBlanc B, Preiksaitis JK. Comparison of LightCycler-Based PCR, COBAS Amplicor CMV Monitor, and pp65 Antigenemia Assays for Quantitative Measurement of Cytomegalovirus Viral Load in Peripheral Blood Specimens from Patients after Solid Organ Transplantation. *Journal of Clinical Microbiology*. 2003;41(7):3167-74.
  16. Boeckh M, Boivin G. Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications. *Clinical Microbiology Reviews*. 1998;11(3):533-54.
  17. Ravanshad M, Sabahi F, Falahi S, Kenarkoohi A, Amini-Bavil-Olaee S, Hosseini SY, et al. Prediction of hepatitis B virus lamivudine resistance based on YMDD. *Hepat Med*. 2011;11:108-13.
  18. Valones MAA, Guimarães RL, Brandão LAC, de Souza PRE, de Albuquerque Tavares Carvalho A, Crovela S. Principles and applications of polymerase chain reaction in medical diagnostic fields: a review. *Brazilian Journal of Microbiology*. 2009;40(1):1-11.
  19. Yamamoto Y. PCR in Diagnosis of Infection: Detection of Bacteria in Cerebrospinal Fluids. *Clinical and Diagnostic Laboratory Immunology*. 2002;9(3):508-14.
  20. Jenkins FJ, Rowe DT, Rinaldo CR. Herpesvirus Infections in Organ Transplant Recipients. *Clinical and Diagnostic Laboratory Immunology*. 2003;10(1):1-7.
  21. Razonable RR, Hayden RT. Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation. *Clinical Microbiology Reviews*. 2013;26(4):703-27.
  22. Weikert BC, Blumberg EA. Viral Infection after Renal Transplantation: Surveillance and Management. *Clinical Journal of the American Society of Nephrology : CJASN*. 2008;3(Suppl 2):S76-S86.
  23. Ramanan P, Razonable RR. Cytomegalovirus Infections in Solid Organ Transplantation: A Review. *Infection & Chemotherapy*. 2013;45(3):260-271.
  24. Carl Ossolano, Isable Munoz, Antonio gutierrez, Amparo Farga, Felipe Prosper, Javier Garcia-Conde, David Navaro. Qualitative Plasma PCR Assay (AMPLICORCMV Test) versus pp65 ntigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation. *Journal of Clinical Microbiology*. 2001;39:38-41.
  25. Schmidt CA, Oettle H, Ruoqi P, Neuhaus P, Blumhardt G, Lohmann R, Wilborn F, Osthoff K, Oertel J, Timm H, Siegert W. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. *Transplantation*. 1995;59(8):1133-8.

## Detection of Cytomegalovirus (CMV ) in Peripheral Blood Specimens ...

26. Lashini H, Goodarzi Z, Hosseini MJ, Saberfar E. Development of PCR assay for early detection of CMV infection in renal transplant recipients. *Nephro-Urol Mon.* 2011;3(2):106-8.

27. Tony Mazzulli, Lawrence W. Drew, Belinda Yen-Lieberman, Dragana Jekic-McMullen, Debra J. Kohn, Carlos Isada, George Moussa, Robert Chua, and Sharon Walmsley. Multicenter Comparison of the Digene Hybrid Capture CMV DNA Assay (Version 2.0), the pp65 Antigenemia Assay, and Cell Culture for Detection of Cytomegalovirus Viremia. *Journal of Clinical Microbiology.* 1999;37(4):958-63.

28. sabelle pelegrine, Isabelle garigue, Christine biquet, Genevieve chene, Didier neau, Pascal bonot, Fabrice bonnet, Herve fleury and Jean-luc pellegrin. Evaluation of new Quantitative assay for diagnosis

and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. *Journal of Clinical Microbiology.* 1999;31:24-32.

29. Haijing Li, Stephen Dummer J, Wray R, Shufang M, Peter F, Yi-Wei T. Measurement of Human Cytomegalovirus Loads by Quantitative Real-Time PCR for Monitoring Clinical Intervention in Transplant Recipients *Journal Of Clinical Microbiology.* 2003;187-91

30. Drago L, Lombardi A, De Vecchi E, Giuseppe Giuliani, Rosaria Bartolone and Maria Rita Gism. Comparison of nested PCR and real time PCR of Herpesvirus infections of central nervous system in HIV patients. *BMC Infectious Diseases.* 2004;4:55.